Thomas P Loughran Jr
Overview
Explore the profile of Thomas P Loughran Jr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
134
Citations
3483
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pu J, Berger K, Zheng C, Do N, Claxton D, Ehmann W, et al.
Front Oncol
. 2024 Dec;
14:1449401.
PMID: 39737396
Clinical Trial Registration: ClinicalTrials.gov, identifier NCT01439750.
2.
Moosic K, Olson T, Freijat M, Khalique S, Hamele C, Shemo B, et al.
Front Immunol
. 2024 Nov;
15:1466276.
PMID: 39497832
Objectives: Large granular lymphocyte (LGL) leukemia is a rare hematologic malignancy characterized by clonal expansion of cytotoxic T-cells frequent somatic activating mutations. Based on the disease overlap between LGL leukemia...
3.
Ung J, Kassai M, Tan S, Loughran Jr T, Feith D, Cabot M
Int J Mol Sci
. 2024 Sep;
25(18).
PMID: 39337312
The tumor-suppressor sphingolipid ceramide is recognized as a key participant in the cytotoxic mechanism of action of many types of chemotherapy drugs, including anthracyclines, Vinca alkaloids, the podophyllotoxin etoposide, taxanes,...
4.
Marchand T, Lamy T, Loughran Jr T
Blood
. 2024 Jun;
144(18):1910-1923.
PMID: 38848524
Large granular lymphocytic leukemia (LGLL) is a rare lymphoproliferative chronic disorder characterized by expansion of either T or natural killer (NK) cytotoxic cells. In contrast to Epstein-Barr virus-induced aggressive NK-LGLL,...
5.
Hagen J, Montgomery M, Aruleba R, Chrest B, Green T, Kassai M, et al.
bioRxiv
. 2024 Apr;
PMID: 38659944
Despite early optimism, therapeutics targeting oxidative phosphorylation (OxPhos) have faced clinical setbacks, stemming from their inability to distinguish healthy from cancerous mitochondria. Herein, we describe an actionable bioenergetic mechanism unique...
6.
Raghuwanshi J, Roberts N, Loughran Jr T, El Chaer F, Girton M, Moulder G
J Gen Intern Med
. 2024 Feb;
39(7):1257-1263.
PMID: 38409513
No abstract available.
7.
Casasampere M, Ung J, Inanez A, Dufau C, Tsuboi K, Casas J, et al.
J Lipid Res
. 2024 Feb;
65(3):100520.
PMID: 38369184
Lipid amidases of therapeutic relevance include acid ceramidase (AC), N-acylethanolamine-hydrolyzing acid amidase, and fatty acid amide hydrolase (FAAH). Although fluorogenic substrates have been developed for the three enzymes and high-throughput...
8.
Assatova B, Willim R, Trevisani C, Haskett G, Kariya K, Chopra K, et al.
Clin Cancer Res
. 2024 Jan;
30(11):2514-2530.
PMID: 38252421
Purpose: Develop a novel therapeutic strategy for patients with subtypes of mature T-cell and NK-cell neoplasms. Experimental Design: Primary specimens, cell lines, patient-derived xenograft models, commercially available, and proprietary anti-KLRG1...
9.
Paudel B, Tan S, Fox T, Ung J, Golla U, Shaw J, et al.
Blood Adv
. 2024 Jan;
8(5):1137-1142.
PMID: 38170742
No abstract available.
10.
Ung J, Tan S, Fox T, Shaw J, Taori M, Horton B, et al.
Cancers (Basel)
. 2023 Dec;
15(24.
PMID: 38136410
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy requiring urgent treatment advancements. Ceramide is a cell-death-promoting signaling lipid that plays a central role in therapy-induced cell death. We previously...